338 related articles for article (PubMed ID: 20656315)
1. Aurora kinase A in Barrett's carcinogenesis.
Rugge M; Fassan M; Zaninotto G; Pizzi M; Giacomelli L; Battaglia G; Rizzetto C; Parente P; Ancona E
Hum Pathol; 2010 Oct; 41(10):1380-6. PubMed ID: 20656315
[TBL] [Abstract][Full Text] [Related]
2. Fatty acid synthase expression in Barrett's esophagus: implications for carcinogenesis.
Ishimura N; Amano Y; Sanchez-Siles AA; Fukuhara H; Takahashi Y; Uno G; Tamagawa Y; Mishima Y; Yuki T; Ishihara S; Kinoshita Y
J Clin Gastroenterol; 2011 Sep; 45(8):665-72. PubMed ID: 21325951
[TBL] [Abstract][Full Text] [Related]
3. Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa--significance of sampling.
Werther M; Saure C; Pahl R; Schorr F; Rüschoff J; Alles JU; Heinmöller E
Pathol Res Pract; 2008; 204(5):285-94. PubMed ID: 18337019
[TBL] [Abstract][Full Text] [Related]
4. Activation of Akt is increased in the dysplasia-carcinoma sequence in Barrett's oesophagus and contributes to increased proliferation and inhibition of apoptosis: a histopathological and functional study.
Beales IL; Ogunwobi O; Cameron E; El-Amin K; Mutungi G; Wilkinson M
BMC Cancer; 2007 Jun; 7():97. PubMed ID: 17559672
[TBL] [Abstract][Full Text] [Related]
5. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
6. The metabolic marker tumour pyruvate kinase type M2 (tumour M2-PK) shows increased expression along the metaplasia-dysplasia-adenocarcinoma sequence in Barrett's oesophagus.
Koss K; Harrison RF; Gregory J; Darnton SJ; Anderson MR; Jankowski JA
J Clin Pathol; 2004 Nov; 57(11):1156-9. PubMed ID: 15509675
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of the MAD2, BUB1 and HSP27 genes in Barrett's oesophagus-their association with aneuploidy and neoplastic progression.
Doak SH; Jenkins GJ; Parry EM; Griffiths AP; Baxter JN; Parry JM
Mutat Res; 2004 Mar; 547(1-2):133-44. PubMed ID: 15013707
[TBL] [Abstract][Full Text] [Related]
8. Barrett's oesophagus: from metaplasia to dysplasia and cancer.
Fléjou JF
Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i6-12. PubMed ID: 15711008
[TBL] [Abstract][Full Text] [Related]
9. Non-goblet cell population of Barrett's esophagus: an immunohistochemical demonstration of intestinal differentiation.
Chaves P; Cardoso P; de Almeida JC; Pereira AD; Leitao CN; Soares J
Hum Pathol; 1999 Nov; 30(11):1291-5. PubMed ID: 10571507
[TBL] [Abstract][Full Text] [Related]
10. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
[TBL] [Abstract][Full Text] [Related]
11. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
[TBL] [Abstract][Full Text] [Related]
12. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
Chatelain D; Fléjou JF
Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
[TBL] [Abstract][Full Text] [Related]
13. Apoptosis and cell proliferation in the metaplasia-dysplasia-carcinoma-sequence of Barrett's esophagus.
Halm U; Tannapfel A; Breitung B; Breidert M; Wittekind CW; Mössner J
Hepatogastroenterology; 2000; 47(34):962-6. PubMed ID: 11020858
[TBL] [Abstract][Full Text] [Related]
14. Esophageal adenocarcinoma arising in cervical inlet patch with synchronous Barrett's esophagus-related dysplasia.
Tanaka M; Ushiku T; Ikemura M; Shibahara J; Seto Y; Fukayama M
Pathol Int; 2014 Aug; 64(8):397-401. PubMed ID: 25143128
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2 (COX-2) is the key event in pathophysiology of Barrett's esophagus. Lesson from experimental animal model and human subjects.
Majka J; Rembiasz K; Migaczewski M; Budzynski A; Ptak-Belowska A; Pabianczyk R; Urbanczyk K; Zub-Pokrowiecka A; Matlok M; Brzozowski T
J Physiol Pharmacol; 2010 Aug; 61(4):409-18. PubMed ID: 20814068
[TBL] [Abstract][Full Text] [Related]
16. [Histochemical diagnosis of short segment Barrett's esophagus].
Fujiyama Y; Ishizuka I; Koyama S
Nihon Rinsho; 2005 Aug; 63(8):1420-6. PubMed ID: 16101233
[TBL] [Abstract][Full Text] [Related]
17. Dedifferentiation precedes invasion in the progression from Barrett's metaplasia to esophageal adenocarcinoma.
Helm J; Enkemann SA; Coppola D; Barthel JS; Kelley ST; Yeatman TJ
Clin Cancer Res; 2005 Apr; 11(7):2478-85. PubMed ID: 15814623
[TBL] [Abstract][Full Text] [Related]
18. Preferential up-regulation of heparanase and cyclooxygenase-2 in carcinogenesis of Barrett's oesophagus and intestinal-type gastric carcinoma.
Sonoda R; Naomoto Y; Shirakawa Y; Fujiwara Y; Yamatsuji T; Noma K; Tanabe S; Takaoka M; Gunduz M; Tsujigiwa H; Nagatsuka H; Ohara N; Yoshino T; Takubo K; Vieth M; Tanaka N
Histopathology; 2010 Jul; 57(1):90-100. PubMed ID: 20653782
[TBL] [Abstract][Full Text] [Related]
19. Mucin expression and proliferating cell index of esophageal Barrett's adenocarcinoma.
Yamamoto S; Kijima H; Hara T; Chino O; Shimada H; Tanaka M; Inokuchi S; Makuuchi H
Int J Mol Med; 2005 Sep; 16(3):375-80. PubMed ID: 16077942
[TBL] [Abstract][Full Text] [Related]
20. Esophageal polypoid dysplasia of gastric foveolar phenotype with focal intramucosal carcinoma associated with Barrett's esophagus.
Asthana N; Mandich D; Ligato S
Am J Surg Pathol; 2008 Oct; 32(10):1581-5. PubMed ID: 18724240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
